Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Rating of “Moderate Buy” by Analysts

Arcus Biosciences, Inc. (NYSE:RCUS) has earned a consensus recommendation of “Moderate Buy” from the eight brokerages that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $41.25.

RCUS has been the topic of several research reports. Mizuho dropped their price target on Arcus Biosciences from $51.00 to $42.00 and set a “buy” rating on the stock in a research report on Tuesday, January 30th. Wedbush restated an “outperform” rating and set a $30.00 price target on shares of Arcus Biosciences in a research report on Thursday, February 22nd. Finally, Truist Financial restated a “buy” rating and set a $50.00 price target on shares of Arcus Biosciences in a research report on Monday, March 25th.

Insider Buying and Selling at Arcus Biosciences

In other Arcus Biosciences news, COO Jennifer Jarrett sold 24,555 shares of Arcus Biosciences stock in a transaction on Monday, February 26th. The stock was sold at an average price of $20.07, for a total transaction of $492,818.85. Following the completion of the transaction, the chief operating officer now owns 274,323 shares in the company, valued at $5,505,662.61. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, President Juan C. Jaen sold 3,900 shares of the business’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $20.06, for a total value of $78,234.00. Following the completion of the transaction, the president now owns 1,211,365 shares in the company, valued at $24,299,981.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Jennifer Jarrett sold 24,555 shares of the business’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $20.07, for a total value of $492,818.85. Following the completion of the transaction, the chief operating officer now owns 274,323 shares of the company’s stock, valued at approximately $5,505,662.61. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 53,455 shares of company stock worth $1,014,779. 13.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of RCUS. Decheng Capital LLC purchased a new position in shares of Arcus Biosciences in the fourth quarter worth $16,613,000. Barclays PLC grew its holdings in shares of Arcus Biosciences by 183.4% in the third quarter. Barclays PLC now owns 470,776 shares of the company’s stock worth $8,451,000 after acquiring an additional 304,683 shares during the period. FMR LLC grew its holdings in shares of Arcus Biosciences by 4.9% in the third quarter. FMR LLC now owns 4,780,052 shares of the company’s stock worth $85,802,000 after acquiring an additional 222,280 shares during the period. Vanguard Group Inc. grew its holdings in shares of Arcus Biosciences by 4.2% in the fourth quarter. Vanguard Group Inc. now owns 4,680,716 shares of the company’s stock worth $89,402,000 after acquiring an additional 186,898 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Arcus Biosciences by 11.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,594,609 shares of the company’s stock worth $30,459,000 after acquiring an additional 158,094 shares during the period. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Arcus Biosciences Stock Performance

Shares of RCUS stock opened at $14.73 on Friday. Arcus Biosciences has a fifty-two week low of $12.95 and a fifty-two week high of $25.47. The firm has a market cap of $1.34 billion, a P/E ratio of -3.55 and a beta of 0.81. The business’s 50 day moving average price is $17.51 and its 200-day moving average price is $16.62.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings results on Wednesday, February 21st. The company reported ($1.08) earnings per share for the quarter, beating the consensus estimate of ($1.09) by $0.01. Arcus Biosciences had a negative return on equity of 57.17% and a negative net margin of 262.39%. The company had revenue of $31.00 million for the quarter, compared to analyst estimates of $28.30 million. During the same period in the previous year, the company posted ($0.93) earnings per share. The firm’s revenue was down 8.8% on a year-over-year basis. As a group, equities analysts predict that Arcus Biosciences will post -3.59 EPS for the current year.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.